Literature DB >> 33428338

Expanding the Spectrum of Microscopic and Cytogenetic Findings Associated With Spitz Tumors With 11p Gains.

Cecilia M Lezcano1, Iwei Yeh2, Nasrin Eslamdoost1, Yuqiang Fang1, Philip E LeBoit2, Timothy H McCalmont2, Andrea P Moy1, Yanming Zhang1, Klaus J Busam1.   

Abstract

A subset of Spitz tumors is associated with a copy number increase of chromosome 11p and activating mutations of HRAS. These aberrations have been reported to occur in association with desmoplastic Spitz nevi. Little is known to what extent 11p gains can also be found in nondesmoplastic tumors. To learn more about the spectrum of microscopic and cytogenetic changes that can be seen in Spitz lesions in association with 11p gains, we reviewed the clinical and pathologic features of 40 cases. Patient ages ranged from 3 to 75 years. The most common anatomic site was the head and neck region, followed by the upper extremities. Prominent desmoplasia was present in 10 cases. Seven tumors lacked significant stromal fibrosis. Twenty tumors were mitotically active. Novel microscopic features encountered in a few cases include a tumor with a polypoid silhouette and papillomatous surface and rare atypical tumors with a deep bulbous growth pattern. Among 36 cases analyzed by single-nucleotide polymorphism array or comparative genomic hybridization, 28 tumors had gains of the entire or near-entire p-arm of chromosome 11 with no other coexisting unbalanced genomic aberration. Eight cases had additional changes; 6 of these with 1 additional aberration per case, and 2 cases had several chromosomal aberrations. We also examined a subset of tumors by fluorescence in situ hybridization for the HRAS gene locus (11p15.5). All tumors were fluorescence in situ hybridization-positive. In conclusion, we expand the spectrum of pathologic findings associated with Spitz tumors with 11p gains. This cytogenetic aberration is not restricted to desmoplastic Spitz nevi. It can also be seen in nondesmoplastic and papillomatous lesions and atypical melanocytic tumors with a deep bulbous growth. We also document that in some Spitz tumors additional cytogenetic aberrations may be found, the significance of which remains to be determined.
Copyright © 2020 Wolters Kluwer Health, Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 33428338      PMCID: PMC7808272          DOI: 10.1097/PAS.0000000000001607

Source DB:  PubMed          Journal:  Am J Surg Pathol        ISSN: 0147-5185            Impact factor:   6.298


  16 in total

1.  Molecular cytogenetic analysis of Spitz nevi shows clear differences to melanoma.

Authors:  B C Bastian; U Wesselmann; D Pinkel; P E Leboit
Journal:  J Invest Dermatol       Date:  1999-12       Impact factor: 8.551

2.  HRAS-mutated Spitz tumors: A subtype of Spitz tumors with distinct features.

Authors:  A C H van Engen-van Grunsven; Marcory C R F van Dijk; Dirk J Ruiter; Annelies Klaasen; Wolter J Mooi; Willeke A M Blokx
Journal:  Am J Surg Pathol       Date:  2010-10       Impact factor: 6.394

3.  Melanocytic tumors of uncertain malignant potential: results of a tutorial held at the XXIX Symposium of the International Society of Dermatopathology in Graz, October 2008.

Authors:  Lorenzo Cerroni; Raymond Barnhill; David Elder; Geoffrey Gottlieb; Peter Heenan; Heinz Kutzner; Philip E LeBoit; Martin Mihm; Juan Rosai; Helmut Kerl
Journal:  Am J Surg Pathol       Date:  2010-03       Impact factor: 6.394

4.  Mutations and copy number increase of HRAS in Spitz nevi with distinctive histopathological features.

Authors:  B C Bastian; P E LeBoit; D Pinkel
Journal:  Am J Pathol       Date:  2000-09       Impact factor: 4.307

5.  Genomic alterations in primary cutaneous melanomas detected by metaphase comparative genomic hybridization with laser capture or manual microdissection: 6p gains may predict poor outcome.

Authors:  Takeshi Namiki; Shigeru Yanagawa; Toshiyuki Izumo; Masashi Ishikawa; Masayoshi Tachibana; Yutaka Kawakami; Hiroo Yokozeki; Kiyoshi Nishioka; Yasuhiko Kaneko
Journal:  Cancer Genet Cytogenet       Date:  2005-02

6.  The Spitzoid lesion: rethinking Spitz tumors, atypical variants, 'Spitzoid melanoma' and risk assessment.

Authors:  Raymond L Barnhill
Journal:  Mod Pathol       Date:  2006-02       Impact factor: 7.842

7.  Recurrent BRAF kinase fusions in melanocytic tumors offer an opportunity for targeted therapy.

Authors:  Thomas Botton; Iwei Yeh; Tyrrell Nelson; Swapna S Vemula; Alyssa Sparatta; Maria C Garrido; Maryline Allegra; Stephane Rocchi; Philippe Bahadoran; Timothy H McCalmont; Philip E LeBoit; Elizabeth A Burton; Gideon Bollag; Robert Ballotti; Boris C Bastian
Journal:  Pigment Cell Melanoma Res       Date:  2013-08-19       Impact factor: 4.693

Review 8.  Atypical Spitz Tumors: A Diagnostic Challenge.

Authors:  Kelly L Harms; Lori Lowe; Douglas R Fullen; Paul W Harms
Journal:  Arch Pathol Lab Med       Date:  2015-10       Impact factor: 5.534

9.  Activating MET kinase rearrangements in melanoma and Spitz tumours.

Authors:  Iwei Yeh; Thomas Botton; Eric Talevich; A Hunter Shain; Alyssa J Sparatta; Arnaud de la Fouchardiere; Thaddeus W Mully; Jeffrey P North; Maria C Garrido; Alexander Gagnon; Swapna S Vemula; Timothy H McCalmont; Philip E LeBoit; Boris C Bastian
Journal:  Nat Commun       Date:  2015-05-27       Impact factor: 14.919

10.  Spitz melanoma is a distinct subset of spitzoid melanoma.

Authors:  Shyam S Raghavan; Sandra Peternel; Thaddeus W Mully; Jeffrey P North; Laura B Pincus; Philip E LeBoit; Timothy H McCalmont; Boris C Bastian; Iwei Yeh
Journal:  Mod Pathol       Date:  2020-01-03       Impact factor: 7.842

View more
  1 in total

Review 1.  The Spectrum of Spitz Melanocytic Lesions: From Morphologic Diagnosis to Molecular Classification.

Authors:  Tiffany W Cheng; Madeline C Ahern; Alessio Giubellino
Journal:  Front Oncol       Date:  2022-06-07       Impact factor: 5.738

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.